The University of San Agustin – Center for Chemical Biology and Biotechnology and Center for Natural Drug Discovery and Development (USA – C2B2 & CND3) proudly celebrates another milestone achievement with the granting of its second Philippine patent, titled:
“𝘔𝘦𝘵𝘩𝘰𝘥𝘴 𝘰𝘧 𝘗𝘶𝘳𝘪𝘧𝘺𝘪𝘯𝘨 𝘈𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤 𝘊𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴 𝘧𝘳𝘰𝘮 𝘊𝘢𝘫𝘢𝘯𝘶𝘴 𝘊𝘢𝘫𝘢𝘯.”
This patented technology describes a method for purifying antibiotic metabolites from kadios seeds, revealing their potential as natural agents against multidrug-resistant Staphylococcus aureus and other skin pathogens. The patent was granted on 10 October 2025 and is valid until 31 August 2042. Its protection strengthens the method’s commercial viability and supports future product development.
This accomplishment highlights the strong academe–industry partnership between USA and Maridan Industries Inc., a progressive regional pharmaceutical company known for its consistent technical excellence and commitment to developing Filipino-made health innovations through its sister company Pharma GalenX. The patented technology serves as the scientific foundation of SKIVIOS®, a locally developed skin formulation that is now commercially available—bringing Filipino science directly to consumers.
This milestone captures the journey where research grows into innovation, innovation matures into technology, and technology leads to shared prosperity, showing how local scientific excellence can uplift communities and strengthen regional development.
This achievement also supports key UN Sustainable Development Goals (SDGs).
It strongly advances SDG 3 (Good Health and Well-Being) through its contribution to developing safe and effective antibiotic agents, and SDG 9 (Industry, Innovation, and Infrastructure) by strengthening local pharmaceutical research and technological capacity. The collaboration between USA and Maridan Industries reflects SDG 17 (Partnerships for the Goals). Indirectly, it contributes to SDG 4 (Quality Education) by enriching research training, and SDG 8 (Decent Work and Economic Growth) by fostering innovations that can support future biotech opportunities.
USA – C2B2 and CND3 extend heartfelt gratitude to DOST-PCHRD for funding this initiative, and to the USA Administrators and the Augustinian Friars for their steadfast support to research and innovation.
This patent stands as a testament to what collaboration, dedication, and Filipino scientific excellence can achieve.
